Related Experiment Videos
Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms
Wei Sun1, Zirong Li, Zhengcai Shi
1Department of Orthopaedic Surgery, Center for Osteonecrosis and Joint Preserving and Reconstruction, China-Japan Friendship Hospital, Beijing, 100029, China, Sun887@163.com.
Summary
Post-severe acute respiratory syndrome (SARS) patients with osteonecrosis show elevated plasminogen activator inhibitor-1 (PAI-1) levels. The 4G/4G PAI-1 genotype may indicate a susceptibility to osteonecrosis in this population.
Area of Science:
- Biomedical research
- Molecular biology
- Clinical investigation
Background:
- Severe acute respiratory syndrome (SARS) can lead to long-term complications, including osteonecrosis.
- The underlying mechanisms and early diagnostic markers for post-SARS osteonecrosis require further investigation.
Purpose of the Study:
- To explore the correlation between SARS and osteonecrosis.
- To investigate the etiology of post-SARS osteonecrosis.
- To identify sensitive molecular markers for early diagnosis and high-risk population stratification.
Main Methods:
- A case-control study comparing 62 post-SARS patients with osteonecrosis and 52 healthy controls.
- Measurement of plasma plasminogen activator inhibitor (PAI) activity using ELISA.
- Detection of PAI-1 4G/5G polymorphism via PCR and oligonucleotide assay.
Main Results:
- Post-SARS patients exhibited significantly higher plasma PAI activity compared to controls (15.64 ± 13.85 U/ml vs. 7.96 ± 4.27 U/ml).
- The 4G/4G genotype of PAI-1 polymorphism was more prevalent in the post-SARS osteonecrosis group, though not statistically significant.
- Plasma PAI activity was associated with the 4G/4G genotype, suggesting a potential genetic predisposition.
Conclusions:
- Plasminogen activator inhibitor-1 (PAI-1) serves as a sensitive biomarker for screening individuals at high risk of developing osteonecrosis.
- The 4G/4G PAI-1 genotype may be an etiological factor contributing to osteonecrosis in post-SARS patients.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...